Canadian M&A activity slowed in the first half of 2023, with 848 companies sold — an 8% drop in deal…
Read More
Sysco’s $29 Billion Bet on Restaurant Depot Sends Shares Plunging 13% as Investors Balk at Soaring Debt
Sysco (NYSE: SYY) fell more than 13% after announcing a $29.1 billion acquisition of Jetro Restaurant Depot, combining $21.6 billion…
Read More
Capital One Begins Absorbing Discover’s Credit Card Systems in $2.7 Billion Synergy Play That Could Reshape U.S. Payments
Capital One Financial plans to migrate Discover credit cards onto its own back-office systems starting July 2026, a critical step…
Read More
Fox’s $25 Billion Streaming Gamble Reshapes the Future of Digital Video
Fox is acquiring a major streaming and connected TV platform in a $25 billion deal, creating one of the industry's…
Read More
Diageo Faces Revenue Slide and Financial Stress Signals Ahead of Critical Earnings Report
Diageo (DEO) is set to release its first-half fiscal earnings on February 25th, with analysts forecasting an EPS of $3.71…
Read More
GSK Bets $10.6 Billion on Two Cancer Drugs Awaiting FDA Approval This Fall
GSK announced Tuesday it will acquire Nuvalent, a cancer drug developer, for $10.6 billion. CEO Luke Miels, six months into…
Read More
Italy’s Banking Giant Intesa Sanpaolo Makes Surprise $35 Billion Move to Swallow Monte dei Paschi and Reshape Europe’s Financial Power
Italy's largest banking group, Intesa Sanpaolo, launched an unsolicited €30.6 billion ($35 billion) cash-and-share bid on Monday, June 8, to…
Read More
Estée Lauder’s Billion-Dollar Merger With Puig Collapsed Under the Weight of Leaks, Family Feuds and a Price War
Estée Lauder's merger talks with Puig, the owner of Jean Paul Gaultier, collapsed over price disagreements, CEO Stéphane de La…
Read More
10 State Attorneys General Race to Block Skydance-Paramount Deal Before July Deadline
Attorneys general from 10 states, including California, New York, Oregon, Nevada, Colorado, Connecticut, Massachusetts, Tennessee, and Pennsylvania, are reportedly exploring…
Read More
Spruce Biosciences Acquires Rare Enzyme Therapy Targeting Fatal Childhood Brain Disease With No Approved Treatments
Spruce Biosciences (Nasdaq: SPRB) has announced a new corporate strategy centered on the acquisition of tralesinidase alfa enzyme replacement therapy…
Read More
